Recent Patents on CNS Drug Discovery

Vincenzo Di Marzo
Istituto di Chimica Biomolecolare (I.C.B.)
Consiglio Nazionale delle Ricerche (C.N.R.)
Via Campi Flegrei 34
Pozzuoli, Napoli 80078
Italy

Back

Recent Advances in the Treatment of Neurogenic Erectile Dysfunction

Author(s): Rocco S. Calabro, Giovanni Polimeni and Placido Bramanti

Affiliation: Neurorehabilitation Unit, IRCCS Centro Neurolesi “Bonino Pulejo” , via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy.

Keywords: Dopaminergic agonists, guanylate-cyclase activators, melanocortins, neurogenic erectile dysfunction, patents, PDEi, potassium channel inhibitors.

Abstract:

Neurogenic erectile dysfunction (ED) can be broadly defined as an inability to sustain or maintain a penile erection owing to a neurological impairment, either centrally or peripherally or both. Although significant advances in the pharmacological treatment of ED have occurred in recent years, especially after the introduction of oral selective phosphodiesterase type 5 inhibitor, the treatment of neurological patients with ED may be challenging for prescribers, given poor data available on this topic and the variety of etiologic factors (iatrogenic, endocrine, psychiatric and psychosocial) to consider. At the same time, several, new oral, local and surgical treatments are available and their efficacy and safety depend on the specific cases. This review provides a comprehensive and updated description of current and future ED therapies, including assigned patents, with a special focus on the treatment of neurogenic erectile dysfunction.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 9
ISSUE: 1
Page: [41 - 53]
Pages: 13
DOI: 10.2174/2212798406666140131122641